Wealth Management for Biotech Executives

As a biotech executive, your wealth may be shaped by forces few traditional financial plans fully account for: clinical trial results, regulatory decisions, equity vesting schedules, trading restrictions and sudden liquidity events. Compensation packages in the biotech field are often weighted heavily toward equity: restricted stock units (RSUs), stock options and performance-based awards that can fluctuate dramatically. In a sector defined by high risk and high reward, the complex task of managing your wealth is among the most important financial challenges you face.

What distinguishes wealth management for you from more conventional financial planning is its layered nature. Concentration in a single company’s stock, restrictions on when you can sell shares and the possibility of a transformative liquidity event all require a level of coordination that general financial advice rarely provides. Add the potential tax implications of your equity compensation, and the need for a strategic, long-term approach becomes clear.

Retirement planning in the life sciences industry carries its own complexities. Your income may be irregular and heavily tied to company performance, making it difficult to build retirement savings through conventional methods alone. Yet the same factors that can make planning difficult also create meaningful opportunities if you approach your finances proactively and with a clear strategy.

In this article, Fisher Investments explores wealth management for biotech executives, from managing equity compensation and navigating insider trading restrictions to building a diversified long-term investment strategy and planning for retirement in the biotech industry.

Four Key Wealth Management Considerations for Biotech Executives

1. Equity Compensation is Often a Major Part of Your Net Worth

Equity compensation may represent the largest component of your total compensation and, over time, net worth. Restricted stock units (RSUs), incentive stock options (ISOs), non-qualified stock options (NQSOs) and performance-based equity awards each come with distinct tax treatments, vesting schedules and exercise considerations. Understanding the differences matters. ISOs may trigger the alternative minimum tax when exercised, while NQSOs and RSUs are typically taxed as ordinary income at vesting or exercise, subject to your plan terms and individual tax circumstances. Making uninformed decisions about when and how to exercise or sell could have significant tax consequences.

A coordinated financial strategy that accounts for the timing of equity events—including vesting dates, option expirations, post-IPO lockup expirations and planned liquidity events—can help you manage your tax exposure and reduce the risks associated with your concentrated equity position. This is where a wealth manager with experience serving biotech executives can be invaluable in helping you navigate these equity events.

2. Insider Trading Restrictions and 10b5-1 Plans

You likely face blackout periods and restrictions on trading company shares during sensitive windows, including earnings releases, clinical data readouts, FDA advisory committee activity, regulatory decisions or merger discussions. These restrictions can limit your flexibility and, without advance planning, may leave you unable to act when market conditions or personal financial needs would otherwise call for it.

One tool that may help you navigate these constraints is a Rule 10b5-1 trading plan. Properly structured Rule 10b5-1 plans can provide you with a prearranged framework for selling shares over time. To rely on the rule’s affirmative defense, plans generally must be adopted in good faith when the executive is not aware of material nonpublic information and must satisfy applicable SEC conditions, including cooling-off-period requirements.

Fisher Investments believes working with a trusted investment adviser to structure these plans as part of a broader wealth management strategy can help you diversify your portfolio more systematically over time.

3. Liquidity Events Can Reshape Your Financial Picture

Few factors affect your financial picture as abruptly as a significant liquidity event. An IPO, acquisition or secondary offering can dramatically alter the value of your equity holdings—and the associated financial complexity—in a short period. Planning for these scenarios is an important part of effective wealth management for biotech executives. Without advance preparation, you may find yourself making urgent, consequential financial decisions with limited flexibility.

Advance preparation can make a substantial difference. Identifying how a potential liquidity event would affect your overall portfolio concentration, tax liability and estate planning objectives before the event occurs allows for a more deliberate and coordinated response. The goal isn’t to predict outcomes but to help ensure that multiple scenarios have been considered and that a plan is in place to thoughtfully navigate each situation.

4. Tax-Efficient Strategies for Your Biotech Executive Compensation

We believe tax planning is inseparable from managing your equity compensation. The gap between short-term and long-term capital gains tax rates can be substantial, and the timing of your option exercises and share sales often has more impact on your after-tax wealth than the underlying investment decisions. Coordinating equity sales with other income events, harvesting losses to offset gains and contributing to tax-advantaged retirement accounts in years of elevated income are all wealth management strategies that can help you manage your overall tax exposure more effectively. Fisher Investments suggests coordinating with a qualified tax professional, alongside your trusted investment adviser, to help ensure your tax-efficient investment strategy fits your unique situation.

Risk Management and Liquidity Planning for Your Wealth

Concentration risk is one of the most significant, and often underappreciated, wealth management challenges you can face as a biotech executive. When a substantial portion of your net worth is tied to a single company's stock, an adverse event such as a failed trial, a regulatory setback or broader sector weakness can have an outsized effect on your overall financial security. Diversification isn’t simply an investment preference in this context; it’s a wealth management priority.

Building liquidity outside of your company equity takes time, particularly given trading restrictions. This is why systematic diversification, through scheduled 10b5-1 sales, directed investing of cash compensation, or other planned strategies, is generally more effective than reactive decision-making. A disciplined investment strategy that accounts for the inherent volatility of the biotech industry while building a diversified portfolio over time can provide greater long-term financial stability.

Liquidity planning also means making sure you have sufficient accessible assets to meet your near-term financial needs without being forced to sell company shares at an inopportune time. This may include maintaining appropriate cash reserves, managing debt levels and structuring equity sales to align with anticipated financial needs and goals. An adviser experienced in providing wealth management for biotech executives can help you develop a strategy to address these risks.

Retirement Planning and Long-Term Investment Strategy in the Life Sciences Industry

Retirement planning for you generally requires more deliberate coordination than it does for most professionals. Your total compensation may vary significantly from year to year depending on company performance, equity vesting and bonus structures. This variability makes consistent contributions to tax-advantaged retirement accounts important, particularly in years when your income is elevated and the tax benefit of contributions is greatest.

Beyond retirement accounts, your long-term investment strategy should account for the reality that your company stock, whatever its current value, shouldn’t form the foundation of your retirement assets. Systematic diversification into a broader portfolio of global equities and potentially other asset classes, depending on your needs and situation, could be an appropriate strategy. A global investment approach that spans geographies and sectors can help reduce your dependence on any single country, company or industry, including the biotech and life sciences industries.

Ultimately, the goal of retirement planning isn’t simply to accumulate assets, but to build an investment portfolio that will support your goals and lifestyle when you retire. For you, this often means thinking carefully about the transition from equity-driven compensation to a portfolio-based income strategy and beginning that transition well before retirement. Given your busy and dynamic career, working with a trusted wealth management adviser who has experience supporting biotech executives can help you develop your retirement plan and design a long-term investment strategy to reach your goals.

Selecting a Wealth Management Adviser Who Understands Biotech Executives

Finding the right wealth manager is consequential for any high net worth individual, but it’s particularly important for you, given the complexities common to your profession. Below are five criteria you should consider when evaluating wealth managers:

1. Investment Approach and Strategy

A wealth manager’s approach to investing should be transparent and grounded in a consistent, documented framework. Strategies that shift with market sentiment or cannot be clearly explained could be a potential concern. Ask advisers to describe their process for building and adjusting portfolios and look for an approach that’s evidence-based and aligned with your long-term goals. You should also ask if they have provided wealth management for biotech executives or others facing potential concentration risk, and if so, how they addressed this challenge in the past.

2. Fee Structure

Understanding how a financial adviser is compensated matters. A fee-only structure, in which the adviser charges a straightforward fee based on the assets they manage on your behalf rather than earning commissions on products, can help align the adviser’s incentives with your outcomes.

3. Fiduciary Standard

A fiduciary adviser is legally required to always put your interests first during the relationship. That’s a meaningful distinction in an industry where many financial professionals are held to different standards and some may only be required to recommend products in your interest at the time of the recommendation. Seeking an adviser who is held to the fiduciary standard can be an important consideration when evaluating wealth managers.

4. Comprehensive Wealth Management Support

Given the challenges your biotech executive career can present, you might consider a wealth management professional who offers comprehensive support beyond simply portfolio management. Working with a firm that can also provide resources in financial planning, estate planning, tax-efficient investing, concentrated stock diversification and retirement income planning can help ensure you have a coordinated, holistic approach to wealth management, tailored to your needs.

5. Personalized Service and Clear Communication

The complexity of your wealth management needs calls for an adviser who invests time in understanding your full picture: your equity compensation structure, career trajectory, family circumstances and long-term goals, rather than applying a generic strategy. Personalized service and transparent, ongoing communication are hallmarks of a quality advisory relationship.

How Fisher Investments Can Help

Fisher Investments is an independent, fee-only investment adviser. Fisher Investments and its affiliates manage over $441 billion for over 210,000 individuals, families, businesses and institutions around the world.*

Fisher Investments understands that you face financial challenges that can differ meaningfully from those of many other high net worth individuals. Concentrated equity positions, complex compensation structures, limited trading windows and the distinctive volatility of the life sciences industry require a comprehensive approach to wealth management tailored to your specific situation, goals and risk profile.

Our portfolio management approach is built around a disciplined, top-down investment process designed to navigate a range of market conditions. You’ll receive dedicated support from investment professionals who take the time to understand your financial picture in its entirety, including equity compensation, concentrated stock exposure, liquidity needs, tax considerations, retirement objectives and estate planning priorities, and work with you to develop a coordinated strategy designed to help you reach your long-term goals.

If you’re ready to build a holistic, long-term approach to managing your wealth, Fisher Investments offers the experience, resources and commitment to client service to help you pursue your financial goals. Contact us today to learn more about our wealth management services for biotech executives.

Learn More About How We Can Help You

*As of 6/30/2026. Includes Fisher Investments and its affiliates.